Sana Biotechnology Congratulates Senior Vice President and Head of T Cell Therapeutics, Terry Fry, M.D., on Additional Role at the University of Colorado’s Gates Institute
12 mai 2022 17h40 HE
|
Sana Biotechnology, Inc
SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that its Senior Vice...
Sana Biotechnology Reports First Quarter 2022 Financial Results and Business Updates
10 mai 2022 16h05 HE
|
Sana Biotechnology, Inc
Plans to present data at multiple scientific conferences in 2022, starting with AACR and ASGCT Q1 2022 cash position of $657.4 million Expect to file INDs this year for ex vivo hypoimmune allogeneic...
Sana Biotechnology to Present at the BofA Securities 2022 Healthcare Conference
04 mai 2022 16h05 HE
|
Sana Biotechnology, Inc
SEATTLE, May 04, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast...
Sana Biotechnology to Present Data from Multiple Preclinical Studies at the American Society of Gene and Cell Therapy 25th Annual Meeting
02 mai 2022 16h35 HE
|
Sana Biotechnology, Inc
SEATTLE, May 02, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that five abstracts...
Sana Biotechnology Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates
16 mars 2022 08h30 HE
|
Sana Biotechnology, Inc
Plans to present data at multiple scientific conferences in 2022 Expects to file INDs for leading CAR T ex vivo program, SC291, and in vivo program, SG295, in 2022 2021 year-end cash position of...
Sana Biotechnology to Present at the 32nd Annual Oppenheimer Healthcare Conference
09 mars 2022 16h05 HE
|
Sana Biotechnology, Inc
SEATTLE, March 09, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast...
Sana Biotechnology to Present Preclinical Data on its Engineered Hypoimmune Allogeneic CAR T Cells at the 2022 American Association for Cancer Research Annual Meeting
08 mars 2022 16h35 HE
|
Sana Biotechnology, Inc
SEATTLE, March 08, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that preclinical data...
Sana Biotechnology Obtains Exclusive License from National Institutes of Health for CD22 CAR Construct
11 janv. 2022 06h00 HE
|
Sana Biotechnology, Inc
License will enable Sana’s in vivo and ex vivo engineered T cell programs for B cell malignancies Technology expected to help address key relapse challenges for CD19-directed CAR T cell therapies ...
Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct
10 janv. 2022 16h30 HE
|
Sana Biotechnology, Inc
SEATTLE and SAN FRANCISCO and SAN JOSE, Calif. and NANJING, China and SUZHOU, China and SHANGHAI, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on...
Sana Biotechnology to Present at the 40th Annual J.P. Morgan Healthcare Conference
04 janv. 2022 16h05 HE
|
Sana Biotechnology, Inc
SEATTLE, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today announced that it will webcast...